Jeremy Launders is an executive with over 25 years of leadership experience in the Biotechnology, Pharmaceutical, and Medical Device Industries. Since October 2020, he is serving as the CEO and President of the Management Board at Bioton S.A., a Polish biopharmaceutical company specializing in total diabetes care and the production and development of Human Insulins, API and final finished drug product. Bioton is the leading company in the production of Recombinant Human Insulin within the European Union.
Jeremy started his career after he earned his degree in Applied Biological Sciences and Biotechnology from Technological University Dublin. His career includes significant roles at prominent multinational companies such as Baxter International, Pfizer Global Supply, and Diasorin International. Before joining Bioton, he was Vice President of Operations and Supply Chain for Bimeda Europe and Canada, where he led strategic product implementations and enhanced operations in highly regulated environments and has a proven track record delivering new product approvals in the US, Canada and the European Union.
Throughout his career, Jeremy has overseen critical functions across R&D, HR, Operations, Supply Chain, Finance, Quality Assurance, and Regulatory Affairs. He has managed technical disciplines including production of API’s using biological technologies, vaccine manufacturing, molecular diagnostics, and sterile injectables. His experience extends to leading acquisitions, technology transfers, and major facility and product divestments in both the U.S. and Europe.
At Bioton, Jeremy is focused on expanding the company’s global reach in diabetes solutions, ensuring a reliable insulin supply, and introducing affordable medicines and healthcare solutions. He emphasizes the integration of biosimilars and digital tools to provide personalized healthcare solutions across generations. Jeremy advocates for responsible use of AI in drug discovery and clinical trials, aiming to enhance operational efficiency in the regulatory approval process.
Jeremy has a patient first mind set and strives for improved cost effectiveness while maintaining high quality standards. He advocates for the use of highly affordable and effective medicines in today’s geopolitical environment and believes that it is more important than ever for the EU to be self-sustaining by producing its own raw materials, API and final dose formulations.
He is a collaborative, purpose-driven leader and stresses the importance of employee engagement, transparency, and sustainability in achieving organizational goals. Under his guidance, Bioton has maintained resilience amid global challenges, such as insulin shortages. He is highly focused on sustainable innovation while bringing healthy competition in the area of Oral Diabetic Therapies and Medical devices here in Poland.
